InsiderTrades.com logo
Joshua Cohen net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Joshua Cohen Biography and Net Worth

Co-Founder of Amylyx Pharmaceuticals
Josh Cohen co-founded Amylyx Pharmaceuticals in 2013 and has served since that time as its Co-CEO and Co-Founder. Josh co-invented AMX0035 and has overseen the growth of Amylyx from its start as a concept dreamed up in a dorm room to its status now as a pre-commercial stage pharmaceutical company. Together with Justin, Josh has raised nearly $250M in financing to support the development of new therapies for ALS and other neurodegenerative diseases. Josh received his Bachelor of Science in Biomedical Engineering from Brown University.

How do I contact Joshua Cohen?

The corporate mailing address for Mr. Cohen and other Amylyx Pharmaceuticals executives is 55 Cambridge Parkway, Suite 6w, Cambridge, MA, 02142. Amylyx Pharmaceuticals can also be reached via phone at 617-682-0917 and via email at [email protected]. Learn More on Joshua Cohen's contact information.

Has Joshua Cohen been buying or selling shares of Amylyx Pharmaceuticals?

Joshua Cohen has not been actively trading shares of Amylyx Pharmaceuticals during the last ninety days. Learn More on Joshua Cohen's trading history.

Who are Amylyx Pharmaceuticals' active insiders?

Amylyx Pharmaceuticals' insider roster includes Camille Bedrosian (Insider), Joshua Cohen (Co-Founder), Joshua Cohen (CEO), Karen Firestone (Director), James Frates (CFO), M Jr (Director), Justin Klee (CEO), Justin Klee (Co-Founder), Gina Mazzariello (Insider), Daphne Quimi (Director), Patrick Yeramian (Insider), and Bernhardt Zeiher (Director). Learn More on Amylyx Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Amylyx Pharmaceuticals?

In the last year, Amylyx Pharmaceuticals insiders bought shares 1 times. They purchased a total of 8,100 shares worth more than $100,845.00. In the last year, insiders at the sold shares 15 times. They sold a total of 294,490 shares worth more than $4,701,360.02. The most recent insider tranaction occured on September, 10th when insider Camille L Bedrosian sold 10,028 shares worth more than $324,907.20. Insiders at Amylyx Pharmaceuticals own 10.9% of the company. Learn More about insider trades at Amylyx Pharmaceuticals.

Information on this page was last updated on 9/10/2026.

Joshua Cohen Insider Trading History at Amylyx Pharmaceuticals

See Full Table

Joshua Cohen Buying and Selling Activity at Amylyx Pharmaceuticals

This chart shows Joshua Cohen's buying and selling at Amylyx Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amylyx Pharmaceuticals Company Overview

Amylyx Pharmaceuticals logo
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.
Read More

Today's Range

Now: $29.96
Low: $29.82
High: $30.70

50 Day Range

MA: $28.32
Low: $17.45
High: $39.66

2 Week Range

Now: $29.96
Low: $10.83
High: $41.14

Volume

423,307 shs

Average Volume

1,670,469 shs

Market Capitalization

$3.34 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A